JP2019521645A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521645A5 JP2019521645A5 JP2018554534A JP2018554534A JP2019521645A5 JP 2019521645 A5 JP2019521645 A5 JP 2019521645A5 JP 2018554534 A JP2018554534 A JP 2018554534A JP 2018554534 A JP2018554534 A JP 2018554534A JP 2019521645 A5 JP2019521645 A5 JP 2019521645A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- nos
- human
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims description 71
- 101150013553 CD40 gene Proteins 0.000 claims description 37
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 37
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 36
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 30
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 235000001014 amino acid Nutrition 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 108010029697 CD40 Ligand Proteins 0.000 claims description 11
- 102100032937 CD40 ligand Human genes 0.000 claims description 11
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 11
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 9
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 9
- 230000002195 synergetic effect Effects 0.000 claims description 9
- -1 CEACAM-1 Proteins 0.000 claims description 8
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 8
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 8
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 7
- 102100035793 CD83 antigen Human genes 0.000 claims description 6
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 6
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 6
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 6
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 6
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 108010087819 Fc receptors Proteins 0.000 claims description 5
- 102000009109 Fc receptors Human genes 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 4
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 claims description 3
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 claims description 2
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 2
- 102100031934 Adhesion G-protein coupled receptor G1 Human genes 0.000 claims description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 230000003844 B-cell-activation Effects 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 101710185679 CD276 antigen Proteins 0.000 claims description 2
- 102100036008 CD48 antigen Human genes 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 2
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 102000000795 Galectin 1 Human genes 0.000 claims description 2
- 108010001498 Galectin 1 Proteins 0.000 claims description 2
- 102100031351 Galectin-9 Human genes 0.000 claims description 2
- 101710121810 Galectin-9 Proteins 0.000 claims description 2
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 claims description 2
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 101000775042 Homo sapiens Adhesion G-protein coupled receptor G1 Proteins 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 2
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 2
- 101001023712 Homo sapiens Nectin-3 Proteins 0.000 claims description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000764622 Homo sapiens Transmembrane and immunoglobulin domain-containing protein 2 Proteins 0.000 claims description 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 claims description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- 102100034980 ICOS ligand Human genes 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 102100035487 Nectin-3 Human genes 0.000 claims description 2
- 102000004473 OX40 Ligand Human genes 0.000 claims description 2
- 108010042215 OX40 Ligand Proteins 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 claims description 2
- 101710174757 T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 claims description 2
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 claims description 2
- 102100026224 Transmembrane and immunoglobulin domain-containing protein 2 Human genes 0.000 claims description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 2
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 230000020411 cell activation Effects 0.000 claims description 2
- 239000002458 cell surface marker Substances 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 14
- 241000282693 Cercopithecidae Species 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- 150000001294 alanine derivatives Chemical group 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229940022014 APC-targeting vaccine Drugs 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022034695A JP2022088417A (ja) | 2016-04-18 | 2022-03-07 | ヒトｃｄ４０に結合するアゴニスト抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324170P | 2016-04-18 | 2016-04-18 | |
| US62/324,170 | 2016-04-18 | ||
| PCT/US2017/028162 WO2017184619A2 (en) | 2016-04-18 | 2017-04-18 | Agonistic antibodies that bind human cd40 and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022034695A Division JP2022088417A (ja) | 2016-04-18 | 2022-03-07 | ヒトｃｄ４０に結合するアゴニスト抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521645A JP2019521645A (ja) | 2019-08-08 |
| JP2019521645A5 true JP2019521645A5 (cg-RX-API-DMAC7.html) | 2020-05-07 |
| JP7038064B2 JP7038064B2 (ja) | 2022-03-17 |
Family
ID=58664791
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554534A Active JP7038064B2 (ja) | 2016-04-18 | 2017-04-18 | ヒトｃｄ４０に結合するアゴニスト抗体およびその使用 |
| JP2022034695A Pending JP2022088417A (ja) | 2016-04-18 | 2022-03-07 | ヒトｃｄ４０に結合するアゴニスト抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022034695A Pending JP2022088417A (ja) | 2016-04-18 | 2022-03-07 | ヒトｃｄ４０に結合するアゴニスト抗体およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US10865244B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3445783A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7038064B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102414558B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN116059351A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017252527A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018071307A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3021328A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201892362A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL262269B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA44723A (cg-RX-API-DMAC7.html) |
| MX (1) | MX393066B (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201808821WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017184619A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9169325B2 (en) | 2010-04-13 | 2015-10-27 | Celldex Therapeutics, Inc. | Antibodies that bind human CD27 and uses thereof |
| US10865244B2 (en) | 2016-04-18 | 2020-12-15 | Celldex Therapeutics, Inc. | Nucleic acids encoding agonistic antibodies that bind CD40 |
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| WO2018071500A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| SG11202002366VA (en) * | 2017-09-19 | 2020-04-29 | Mab Discovery Gmbh | Agonistic cd40 antibodies |
| CN109971717B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 共表达cd40抗体与间皮素特异性嵌合抗原受体的t细胞及其用途 |
| CN109971723B (zh) * | 2017-12-28 | 2023-07-07 | 上海细胞治疗研究院 | 包含CD40抗体与muc1特异性嵌合抗原受体基因的T细胞及其用途 |
| WO2019129644A1 (en) * | 2017-12-28 | 2019-07-04 | Julius-Maximilians-Universität Würzburg | TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA) |
| KR20210011919A (ko) | 2018-04-17 | 2021-02-02 | 셀덱스 쎄라퓨틱스, 인크. | 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물 |
| EP3781203A4 (en) | 2018-04-20 | 2022-04-13 | Lyvgen Biopharma Co., Ltd. | Anti-cd40 antibodies and uses thereof |
| AU2018432434B2 (en) * | 2018-07-20 | 2025-11-20 | Eucure (Beijing) Biopharma Co., Ltd | Anti-CD40 antibodies and uses thereof |
| KR20210070317A (ko) | 2018-09-28 | 2021-06-14 | 리브젠 바이오파마 코., 엘티디. | 조작된 Fc 도메인을 갖는 항-CD40 결합 분자 및 그의 치료적 용도 |
| AU2019383548A1 (en) * | 2018-11-23 | 2021-06-24 | Strike Pharma Ab | Bi-specific conjugates |
| CN109734813B (zh) | 2019-01-28 | 2022-06-17 | 广东昭泰体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
| CN109912717B (zh) * | 2019-03-04 | 2020-05-26 | 北京天广实生物技术股份有限公司 | 结合cd40的抗体及其用途 |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| JP7640466B2 (ja) * | 2019-03-27 | 2025-03-05 | アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル | Ｃｄ４０活性化特性を有する組換えタンパク質 |
| AU2020256828A1 (en) * | 2019-04-10 | 2021-11-18 | Nankai University | Anti-CD40 antibody and use thereof |
| WO2021048135A1 (en) | 2019-09-09 | 2021-03-18 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| IL293450A (en) | 2019-12-03 | 2022-07-01 | Evotec Int Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| KR20220117300A (ko) | 2019-12-20 | 2022-08-23 | 암젠 인크 | 고형 종양의 치료를 위한 메소텔린-표적화 cd40 작용성 다중특이성 항체 작제물 |
| AR121013A1 (es) * | 2020-01-10 | 2022-04-06 | Symphogen As | Anticuerpos anti-cd40 y composiciones |
| TWI851885B (zh) * | 2020-03-30 | 2024-08-11 | 大陸商正大天晴藥業集團股份有限公司 | 結合cd40的抗體及其用途 |
| GB202008003D0 (en) * | 2020-05-28 | 2020-07-15 | Quine Medical Ab | Anti-CD40 antibody |
| AU2021283455A1 (en) * | 2020-06-04 | 2023-01-19 | Selvax Pty Ltd | Agonist anti-CD40 antibodies |
| IL298946A (en) | 2020-06-18 | 2023-02-01 | Genentech Inc | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| PE20230839A1 (es) | 2020-06-22 | 2023-05-19 | Ngm Biopharmaceuticals Inc | Agentes de union a lair-1 y metodos para su uso |
| CN116234909A (zh) * | 2020-08-21 | 2023-06-06 | 上海药明生物技术有限公司 | Cd40激动剂抗体和使用方法 |
| TWI799959B (zh) * | 2020-08-21 | 2023-04-21 | 大陸商上海藥明生物技術有限公司 | Cd40激動劑抗體和使用方法 |
| EP4259193A4 (en) | 2020-12-09 | 2025-01-15 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| US20240109973A1 (en) * | 2020-12-16 | 2024-04-04 | Memorial Sloan Kettering Cancer Center | Cd40 binding molecules and uses thereof |
| EP4267176A1 (en) * | 2020-12-23 | 2023-11-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells |
| CN117157320A (zh) * | 2021-01-29 | 2023-12-01 | 国家健康科学研究所 | 沙眼衣原体抗原性多肽及其用于疫苗目的的用途 |
| WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| CN118201636A (zh) * | 2021-10-26 | 2024-06-14 | 萨摩亚商柏沛生医股份有限公司 | 抗癌症及感染性疾病的组合疗法 |
| WO2023077521A1 (en) | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Anti-ilt4 and anti-pd-1 bispecific constructs |
| KR20240166575A (ko) * | 2022-04-02 | 2024-11-26 | 하버 바이오메드 (상하이) 컴퍼니 리미티드 | Pd-l1 및 cd40을 표적화하는 항원 결합 단백질, 이의 제조 방법 및 응용 |
| US20250215100A1 (en) * | 2022-04-02 | 2025-07-03 | Harbour Biomed (Shanghai) Co., Ltd | Antigen binding protein targeting cd40, and preparation therefor and use thereof |
| WO2023213763A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab |
| WO2023213764A1 (en) | 2022-05-02 | 2023-11-09 | Transgene | Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf |
| WO2023232036A1 (zh) | 2022-05-31 | 2023-12-07 | 明济生物制药（北京）有限公司 | 抗cd40抗体和抗pd-l1×cd40双特异抗体及其应用 |
| KR20250022049A (ko) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법 |
| JP2025523573A (ja) | 2022-07-01 | 2025-07-23 | トランジェーヌ | サーファクタントタンパク質－ｄとｔｎｆｓｆのメンバーを含んでなる融合タンパク質 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| US5182368A (en) | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| EP0304578B1 (en) | 1987-06-22 | 2001-10-24 | Medeva Holdings Bv | Peptide comprising hepatitis B surface antigen |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| DE318216T1 (de) | 1987-11-18 | 1990-06-13 | Chiron Corp., Emeryville, Calif. | Nanbv-diagnostika und vakzine. |
| US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE68929323T2 (de) | 1988-12-16 | 2002-04-18 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Pneumolysin-mutanten und pneumokokken-impfstoffe daraus |
| HU225068B1 (en) | 1989-03-17 | 2006-05-29 | Chiron Corp | Process for producing diagnostics and vaccine of nanbh |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| SG48175A1 (en) | 1989-07-25 | 1998-04-17 | Smithkline Beecham Biolog | Novel antigens and method for their preparation |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| EP0593592B1 (en) | 1991-07-08 | 1998-03-25 | The University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
| DE4123760C2 (de) | 1991-07-18 | 2000-01-20 | Dade Behring Marburg Gmbh | Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2 |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5620886A (en) | 1993-03-18 | 1997-04-15 | Ludwig Institute For Cancer Research | Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP3675819B2 (ja) | 1993-10-01 | 2005-07-27 | イミュネックス・コーポレーション | Ｃｄ４０に対する抗体 |
| DE69433820T2 (de) | 1993-12-23 | 2005-06-23 | Immunex Corp., Seattle | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
| EP1167378B1 (en) | 1994-07-15 | 2011-05-11 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| EP0812358A1 (en) | 1995-02-24 | 1997-12-17 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
| CA2213798C (en) | 1995-03-01 | 2001-02-06 | Immunex Corporation | Method for stimulating an immune response |
| IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| US5840306A (en) | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
| US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| US7341727B1 (en) | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
| US6069233A (en) | 1996-10-03 | 2000-05-30 | Memorial Sloan-Kettering Cancer Center | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| WO1999003884A2 (en) | 1997-07-21 | 1999-01-28 | North American Vaccine, Inc. | Modified immunogenic pneumolysin, compositions and their use as vaccines |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| TR200002930T2 (tr) | 1998-04-09 | 2000-12-21 | Smithkline Beecham Biologicals S.A. | Kolaylaştırıcı kompozisyonlar |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| IL148021A0 (en) | 1999-08-23 | 2002-09-12 | Dana Farber Cancer Inst Inc | Novel b7-4 molecules and uses therefor |
| WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US6774226B1 (en) | 1999-11-30 | 2004-08-10 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| AU2001255196A1 (en) | 2000-03-29 | 2001-10-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing immunogenicity of antigens |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| US7063845B2 (en) * | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| JP2002088186A (ja) | 2000-09-14 | 2002-03-27 | Showa Highpolymer Co Ltd | 難燃性フェノ−ル樹脂発泡体の製造方法 |
| US6794501B2 (en) | 2001-05-04 | 2004-09-21 | Ludwig Institute For Cancer Research | Colon cancer antigen panel |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| US20050013809A1 (en) | 2002-12-02 | 2005-01-20 | Owens Samuel M. | Antibodies against drugs of abuse |
| AU2004287480B2 (en) | 2003-11-04 | 2011-09-15 | Novartis Vaccines And Diagnostics, Inc. | Use of antagonist anti-CD40 antibodies for treatment of chronic lymphocytic leukemia |
| DK1682180T3 (da) | 2003-11-04 | 2010-01-11 | Novartis Vaccines & Diagnostic | Monoklonale antagonist-anti-CD40-antistoffer og fremgangsmåder til anvendelse deraf |
| EP1684869B1 (en) | 2003-11-04 | 2011-07-20 | Novartis Vaccines and Diagnostics, Inc. | Methods of therapy for b cell-related cancers |
| DE602004028272D1 (de) | 2003-11-04 | 2010-09-02 | Novartis Vaccines & Diagnostic | Verwendung von antagonisten-anti-cd40-monoklonalen antikörpern zur behandlung von multiplem myelom |
| DK1680141T3 (da) | 2003-11-04 | 2010-11-01 | Novartis Vaccines & Diagnostic | Fremgangsmåder til terapi til faste tumorer der udtrykker CD40-celleoverfladeantigenet |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| CA2588613C (en) | 2004-11-23 | 2010-09-14 | Pip Co., Ltd. | Built-in wall water service box |
| WO2006068953A2 (en) | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| CN101212967A (zh) | 2005-05-10 | 2008-07-02 | 因塞特公司 | 吲哚胺2,3-双加氧酶调节剂及其用法 |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| EP2589654A1 (en) * | 2006-05-03 | 2013-05-08 | The Regents of the University of Colorado, a body corporate | CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| CA2663057C (en) | 2006-09-19 | 2015-12-08 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| JP2010508819A (ja) | 2006-11-02 | 2010-03-25 | ジェネンテック インコーポレイテッド | ヒト化抗ｄ因子抗体 |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| WO2009026303A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Human c-fms antigen binding proteins |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| EP2227233B1 (en) | 2007-11-30 | 2013-02-13 | Newlink Genetics | Ido inhibitors |
| DK2234620T3 (en) | 2008-01-03 | 2016-06-06 | Université D'aix-Marseille | Triple therapy used for treatment of an hiv-infected patient |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| UA106354C2 (ru) | 2008-07-16 | 2014-08-26 | Инститьют Фо Рисерч Ин Байомедсин | Антитела, нейтрализующие цитомегаловирус человека, и их применение |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR20110059755A (ko) * | 2008-09-19 | 2011-06-03 | 메디뮨 엘엘씨 | 소닉 헤지혹 호모로그에 대한 항체 및 이의 용도 |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| CN103382222B (zh) | 2009-03-20 | 2016-12-28 | 安姆根有限公司 | α-4-β-7异二聚体特异性拮抗剂抗体 |
| CA3018235C (en) | 2009-03-20 | 2021-01-12 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| US20110007023A1 (en) | 2009-07-09 | 2011-01-13 | Sony Ericsson Mobile Communications Ab | Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device |
| ES2601226T3 (es) | 2009-10-28 | 2017-02-14 | Newlink Genetics Corporation | Derivados de imidazol como inhibidores de IDO |
| MX343747B (es) | 2009-11-24 | 2016-11-22 | Medimmune Ltd | Agentes de union diana contra b7-h1. |
| CN105218672A (zh) | 2009-12-10 | 2016-01-06 | 霍夫曼-拉罗奇有限公司 | 优先结合人csf1r胞外域4的抗体及其用途 |
| EP2982380B1 (en) | 2010-03-04 | 2021-09-01 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| CN112480256A (zh) | 2010-05-04 | 2021-03-12 | 戊瑞治疗有限公司 | 结合csf1r的抗体 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| AU2011275749C1 (en) | 2010-07-09 | 2015-09-17 | Aduro Biotech Holdings, Europe B.V. | Agonistic antibody to CD27 |
| DK2614082T3 (en) | 2010-09-09 | 2018-11-26 | Pfizer | 4-1BB BINDING MOLECULES |
| CA2824389A1 (en) | 2011-01-10 | 2012-07-19 | Emory University | Antibodies directed against influenza |
| IT1403661B1 (it) * | 2011-01-28 | 2013-10-31 | Probiotical Spa | Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali. |
| EP2681242B1 (en) * | 2011-03-01 | 2018-01-24 | Amgen Inc. | Sclerostin and dkk-1 bispecific binding agents |
| NO2694640T3 (cg-RX-API-DMAC7.html) | 2011-04-15 | 2018-03-17 | ||
| PT2699264T (pt) | 2011-04-20 | 2018-05-23 | Medimmune Llc | Anticorpos e outras moléculas que ligam b7-h1 e pd-1 |
| MX349096B (es) | 2011-11-28 | 2017-07-11 | Merck Patent Gmbh | Anticuerpos anti-pd-l1 y sus usos. |
| CA2853889A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| WO2013119716A1 (en) | 2012-02-06 | 2013-08-15 | Genentech, Inc. | Compositions and methods for using csf1r inhibitors |
| BR112014021251A2 (pt) | 2012-03-02 | 2017-06-27 | Regeneron Pharma | anticorpos humanos para toxinas de clostridium difficile |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| CN104284678B (zh) | 2012-03-15 | 2018-04-24 | 詹森生物科技公司 | 人抗cd27抗体、方法和用途 |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| JP2015517490A (ja) | 2012-05-11 | 2015-06-22 | ファイブ プライム セラピューティックス インコーポレイテッド | コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法 |
| EA037351B8 (ru) | 2012-05-15 | 2021-04-29 | Бристол-Майерс Сквибб Компани | Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4 |
| JP6136343B2 (ja) | 2012-06-12 | 2017-05-31 | 株式会社リコー | 情報処理システム、情報処理方法、プログラム、及び記録媒体 |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| BR112015004426A2 (pt) | 2012-08-31 | 2018-08-28 | Five Prime Therapeutics, Inc. | método para reduzir o nível, tratar uma condição, tratar uma condição inflamatória, tratar distúrbio de cd16+, tratar um respondente inadequado de metotrexate, tratar um respondente inadequado de inibidor de tnf, indentificar um sujeito, predizer responsividade e métodos para tratar uma condição inflamatória |
| KR102270618B1 (ko) | 2012-10-30 | 2021-06-30 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| EP2970448B1 (en) | 2013-03-14 | 2021-11-03 | Regeneron Pharmaceuticals, Inc. | Human antibodies to grem 1 |
| US10072076B2 (en) | 2013-03-14 | 2018-09-11 | Regeneron Pharmaceuticals, Inc. | Human antibodies to NAv1.7 |
| BR112016001420A2 (pt) | 2013-08-02 | 2018-01-23 | Aduro Biotech Holdings Europe B V | combinação de agonistas de cd27 e inibição pontual imune para estimulação imune |
| CA2921639A1 (en) | 2013-09-05 | 2015-03-12 | Aduro Biotech Holdings, Europe B.V. | Cd70-binding peptides and method, process and use relating thereto |
| KR102264548B1 (ko) | 2014-11-21 | 2021-06-16 | 삼성전자주식회사 | 반도체 패키지 및 그 제조 방법 |
| MA43186B1 (fr) | 2015-11-03 | 2022-03-31 | Janssen Biotech Inc | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
| US10865244B2 (en) | 2016-04-18 | 2020-12-15 | Celldex Therapeutics, Inc. | Nucleic acids encoding agonistic antibodies that bind CD40 |
-
2017
- 2017-04-18 US US15/490,589 patent/US10865244B2/en active Active
- 2017-04-18 EA EA201892362A patent/EA201892362A1/ru unknown
- 2017-04-18 KR KR1020187032872A patent/KR102414558B1/ko active Active
- 2017-04-18 WO PCT/US2017/028162 patent/WO2017184619A2/en not_active Ceased
- 2017-04-18 JP JP2018554534A patent/JP7038064B2/ja active Active
- 2017-04-18 CN CN202211384060.9A patent/CN116059351A/zh active Pending
- 2017-04-18 SG SG11201808821WA patent/SG11201808821WA/en unknown
- 2017-04-18 US US16/094,737 patent/US12297266B2/en active Active
- 2017-04-18 MX MX2018012757A patent/MX393066B/es unknown
- 2017-04-18 CA CA3021328A patent/CA3021328A1/en active Pending
- 2017-04-18 BR BR112018071307-4A patent/BR112018071307A2/pt not_active Application Discontinuation
- 2017-04-18 SG SG10201913248VA patent/SG10201913248VA/en unknown
- 2017-04-18 EP EP17720927.7A patent/EP3445783A2/en active Pending
- 2017-04-18 AU AU2017252527A patent/AU2017252527A1/en not_active Abandoned
- 2017-04-18 MA MA044723A patent/MA44723A/fr unknown
- 2017-04-18 CN CN201780024144.2A patent/CN109071665B/zh active Active
-
2018
- 2018-10-10 IL IL262269A patent/IL262269B2/en unknown
-
2019
- 2019-04-05 US US16/376,585 patent/US10633444B2/en active Active
-
2020
- 2020-08-06 US US16/986,613 patent/US10941201B2/en active Active
-
2021
- 2021-01-08 US US17/145,052 patent/US20210147538A1/en not_active Abandoned
-
2022
- 2022-03-07 JP JP2022034695A patent/JP2022088417A/ja active Pending
-
2024
- 2024-06-21 US US18/749,869 patent/US20250115663A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521645A5 (cg-RX-API-DMAC7.html) | ||
| US10233258B2 (en) | Bispecific binding proteins that bind CD40 and mesothelin | |
| JP7366543B2 (ja) | Ｂｃｍａ結合分子及びその使用方法 | |
| JP2021193096A (ja) | Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法 | |
| JP2020522495A (ja) | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| JP2019509055A (ja) | 多特異性免疫調節抗原結合構築物 | |
| JP7680208B2 (ja) | 抗ｃｄ２７抗体およびその使用 | |
| HK1249532A1 (zh) | 具有激动剂活性的抗原结合复合体及使用方法 | |
| JP7646542B2 (ja) | 新規アンタゴニスト抗ｔｎｆｒ２抗体分子 | |
| US20240067740A1 (en) | Antibodies to tnfr2 and uses thereof | |
| CN114127112A (zh) | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 | |
| KR20240073008A (ko) | Cd137 및 종양 연관 항원에 결합하는 이중특이적 결합 단백질 | |
| JP7754506B2 (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| JP2025041695A (ja) | 抗体および使用方法 | |
| JP2022535410A (ja) | Ｔａｃｉを標的とする抗体及びキメラ抗原受容体 | |
| TWI867138B (zh) | 抗tnfr2抗體及其用途 | |
| US20250002599A1 (en) | Bispecific and trispecific binding proteins to pd-l1, cd137, and/or tgf-beta and uses thereof | |
| US20250388676A1 (en) | Binding proteins comprising an anti-immune checkpoint antibody or a fragment thereof and single-chain tnfrsf ligand multimers | |
| CN117425675A (zh) | Tnfr2抗体及其用途 | |
| WO2025262304A1 (en) | Binding proteins comprising an anti-immune checkpoint antibody or a fragment thereof and single-chain tnfrsf ligand multimers | |
| EA045980B1 (ru) | Антитела против рецептора полиовируса (pvr) и их применение | |
| EA042365B1 (ru) | Бифункциональное антитело против ctla4 и против pd-1, его фармацевтическая композиция и их применение |